Genfit: Launch of NASHnext liver disease test lifts shares

Genfit SA

03/05/2021 08:25

** Shares in Genfit  GNFT.PA  rise nearly 5% after the drug
developer announced the launch of NASHnext, a noninvasive
diagnostic test for nonalcoholic steatohepatitis (NASH)
    ** The test is offered exclusively in the United States and
Canada through Labcorp, says Genfit
    ** "NASHnext has the potential to substantially benefit very
large patient populations by providing people with essential
information regarding their liver health," says Labcorp
Diagnostics' Chief Medical Officer Brian Caveney
    ** The stock is on the top of France's SBF 120 index
 .SBF120  on Monday

 ((sarah.morland@thomsonreuters.com; +48 58 769 65 92;))